Ganciclovir ReadyMade™ Solution is provided as a sterile solution formulated in DMSO at a concentration of 2.55 mg/ml. Ganciclovir is an antiviral agent derived from guanine, and is an oxopurine and member of the 2-aminopurines. It is a synthetic analog of 2'-deoxy-guanosine that was patented in 1980. It is active against cytomegalovirus (CMV) and is used in immunology studies. In vivo, it is used in organ transplant applications.
We also offer:
- Ganciclovir (G002)
|Mechanism of Action||
Ganciclovir is first phosphorylated to Ganciclovir monophosphate by a viral kinase encoded by the cytomegalovirus (CMV) gene UL97. After that, cellular kinases convert this molecule to ganciclovir-5'-triphosphate which specifically targets cytomegalovirus (CMV) DNA polymerase since it is a competitive inhibitor of dGTP thus it gets incorporated into DNA and and inhibits viral DNA polymerases more than the cellular DNA polymerases, resulting in termination of viral DNA elogation.
Ganciclovir can be used in a cell-free assay for herpesvirus type-1.
Ganciclovir is commonly used in suceptibility testing for cytomegalovirus (CMV). A rapid phenotypic susceptibility assay was used to detect resistance to Ganciclovir and found that in one study, a strain of CMV became resistant after only 1 month. Thus, the assay of CMV susceptibilty to Ganciclovir could be very helpful in clinical applications (de Oñar, 2002).
Several mutations in UL97 appear to be common markers for Ganciclovir resistance, and their detection may be a rapid alternative to conventional cell culture susceptibility testing for cytomegalovirus (CMV).
|Eukaryotic Cell Culture Applications||Human trabecular meshwork (TM) cells support CMV replication and this model system can be used to study the ocular disease uveitis. When TM cells were exposed to Ganciclovir, a concentration of 10 umol of the compound was found to significantly reduce the accumulation of viral DNA (Choi et al, 2017).|
Choi JA et al (2017) Enhanced cytomegalovirus infection in human trabecular meshwork cells and its implication in glaucoma pathogenesis. Sci. Rep. 7 43349 PMID 28240260
de Oña NM et al (2002) Assay of cytomegalovirus susceptibility to Ganciclovir in renal and heart transplant recipients. Transpl. Int. 15(11):570-573 PMID 12461662
Matthews T and Boehme R (1988) Antiviral activity and mechanism of action of Ganciclovir. Rev. Infect. Dis. 3 (1988): 490-494 PMID 2847285
Trousdale MD, Goldschmidt PL and Nobrega R (year) Activity of Canciclovir against human adenovirus type-5 infection in cell culture and cotton rate eyes. Cornea. 1994 Sep;13(5):435-439 PMID 7995068
Chou S et al (1995) Analysis of the Ul97 phosphotransferase coding sequence In clinical cytomegalovirus isolates and identification of mutations conferring Ganciclovir resistance. J. Infect. Dis. 171 (3):576–583 PMID 7876604